| 0.06855 0 (0.07%) | 09-26 14:52 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.11 | 1-year : | 0.15 |
| Resists | First : | 0.1 | Second : | 0.12 |
| Pivot price | 0.06  |
|||
| Supports | First : | 0.05 | Second : | 0.04 |
| MAs | MA(5) : | 0.06 |
MA(20) : | 0.08 |
| MA(100) : | 0.14 |
MA(250) : | 0.44 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16.2 |
D(3) : | 10.5 |
| RSI | RSI(14): 38.7 |
|||
| 52-week | High : | 3.39 | Low : | 0.05 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BPTH ] has closed below upper band by 47.2%. Bollinger Bands are 8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.07 - 0.07 | 0.07 - 0.07 |
| Low: | 0.06 - 0.06 | 0.06 - 0.06 |
| Close: | 0.07 - 0.07 | 0.07 - 0.07 |
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Tue, 24 Jun 2025
Bio-Path Holdings Faces Leadership Changes and Operational Pause - TipRanks
Tue, 24 Jun 2025
Bio-Path Holdings announces executive resignations and operational pause - Investing.com
Mon, 09 Jun 2025
Bio-Path Showcases Revolutionary DNAbilize Cancer Treatment: Phase 2 Results Coming - Stock Titan
Fri, 23 May 2025
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025 - The Manila Times
Fri, 28 Mar 2025
Bio-Path Slashes Annual Losses While Breakthrough Obesity Treatment Shows Promise - Stock Titan
Wed, 05 Mar 2025
BIO-PATH HOLDINGS Earnings Preview: Recent $BPTH Insider Trading, Hedge Fund Activity, and More - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 5.2 (%) |
| Shares Short | 79 (K) |
| Shares Short P.Month | 250 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.87 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -278.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.11 |
| PEG Ratio | 0 |
| Price to Book value | -0.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|